FDA Sets Outcomes Benchmarks For Actual Use Trials
This article was originally published in The Tan Sheet
Executive Summary
FDA is providing OTC switch application sponsors with pre-defined benchmarks for actual use trials, Center for Drug Evaluation and Research executive Andrea Leonard-Segal says
You may also be interested in...
FDA Panel To Influenza Home MedKit Sponsors: Get Real
Roche begins label comprehension studies this month to support development of aTamiflu home MedKit for the treatment or prophylaxis of pandemic influenza virus, under an initiative driven by the Department of Health and Human Services
Overhaul Of NDAC Process Needed For Better Switch Chances – Brass
FDA should "anchor" advisory committees' evaluations of switch applications by identifying adequate outcomes of behavioral science studies that sponsors submit, according to pharmacology expert Eric Brass
Advisory Panel Meeting Menu Includes Self-Selection Risk/Benefit Evaluation
FDA's Nonprescription Drugs Advisory Committee will tackle issues such as weighing the risks of self-selection failures against the benefit of successes when the panel convenes Sept. 25 to discuss OTC drug consumer behavior trials